trending Market Intelligence /marketintelligence/en/news-insights/trending/SmxVw59efk1VvOdWAyPYgQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

GSK gets EU approval for 2 self-delivery methods for asthma drug Nucala

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


GSK gets EU approval for 2 self-delivery methods for asthma drug Nucala

GlaxoSmithKline PLC said the European Commission has approved two new methods of administering its asthma drug Nucala.

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the autoinjector and a pre-filled safety syringe delivery method for EU approval in May. Both options are to be administered by patients or caregivers once every four weeks after a healthcare professional decides it is appropriate.

The new marketing authorization is based on data from two late-stage studies, called NCT03099096 & NCT03021304. The ability to self-administer the drug through these methods was really popular among participants and 96% preferred these options over going to the clinic for the medication.

The U.S. Food and Drug Administration approved the use of autoinjector and pre-filled safety syringe to administer Nucala in June.

Nucala is approved in over 20 markets including the U.S. and Europe as an add-on maintenance treatment for patients with severe eosinophilic asthma, which is caused by high levels of white blood cells known as eosinophils.